Mechanisms of dexamethasone-induced bone toxicity in developing bone: a single-cell perspective

Area of Science:

• Pediatric Endocrinology
• Developmental Biology
• Pharmacology

Background:

• Glucocorticoids like dexamethasone are vital for treating severe pediatric conditions.
• Long-term dexamethasone use risks pediatric bone health and lifelong skeletal integrity.
• Understanding dexamethasone's bone impact is crucial for pediatric patient care.

Purpose of the Study:

• Elucidate molecular mechanisms of dexamethasone-induced bone toxicity in developing bones.
• Investigate dexamethasone's effects on bone and bone marrow cells using single-cell transcriptomics.
• Determine how dexamethasone impacts pediatric bone development and cellular function.

Main Methods:

• Skeletally immature mice treated with dexamethasone for 28 days.
• Micro-computed tomography assessed bone architecture.
• Single-cell RNA sequencing characterized bone and bone marrow cells.

Main Results:

• Reduced osteoblast and chondrocyte populations; impaired pre-osteoblast function.
• Dexamethasone depleted early B cell progenitors but allowed some immature B cells to persist.
• Decreased longitudinal bone growth, compromised bone architecture, and increased fragility observed.
• Dexamethasone did not enhance osteoclast activity in this pediatric model.

Conclusions:

• Dexamethasone's adverse bone effects stem from impacts on osteoblastic, chondroblastic, and B cell lineages.
• Disruption of cell signaling crosstalk affects bone development and hematopoiesis.
• Findings highlight dexamethasone's complex effects on pediatric skeletal and immune systems.